General Info
Debiopharm Group is a biopharmaceutical development specialist that in-licenses promising biologics and small molecule drug.
Location: Lausanne
Country:
Industries:
Investment Regions: EU
Investment Stages: late-stage, series-a
Website: http://www.debiopharm.com/
EU
Want to start building warm intros with this investor?
🤖 AI Activity Report
Status: very-active
AI Reasoning: Debiopharm (Debiopharm Innovation Fund) has press releases showing investments in 2025: most recently March 25, 2025 (Raidium) and January 29/28, 2025 (Genialis, Hope AI), and site-wide press releases show activity through October 30, 2025 (e.g., NetTargets). The latest investment-related press release (March 25, 2025 – Raidium) is within 3 months of early 2025; additionally October 30, 2025 press releases indicate ongoing activity. The most recent identified investment activity is within the last 3 months, so tag accordingly.
Here are the thresholds established for the different statuses:
Not Active – No known investments in the last 12 months.
Low Activity – Only known investments between the last 12 and 6 months.
Active – Known investments between the last 6 and 3 months.
Very Active – Known investments in the last 3 months.
Investor Contact
Team Members
Name
Role
Email
LinkedIn
…
…
…
…
…
Warm Intros from Portfolio Companies
Investment Regions Map
loading map…
Similar Investors
Other similar investors:
Latest on X (Twitter)
Access all contact details of Debiopharm Group
Gain instant access to partner names, verified emails, LinkedIn profiles, and more—all in one place. Dive into their portfolio founders and their LinkedIn information, so you can quickly start your outreach and look for warm intros.
Add custom tags to your investor cards. Label them by investment stage, industry focus, interest level, or any other criteria you want to stay organized.
Trusted by Founders like You
Find your matching investors using AI